Install
The analyzed dataset included over 200,000 patients with vitiligo to find trends in diagnosis, treatment, and more. The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval. Serota and other field experts discussed best practices as well as new t
- 44articles · 180d
- 2+ day agolatest article
- Mar 25, 2026earliest in window
- 84%with images
- 205avg words
- Medical 44
- Health 40
- Health & Wellness 37
- Beauty & Fitness 6
- Human Interest 2
- Computers & Electronics 1
- Education 1
- Science & Technology 1
- dermatology
- skin health
- 83rd american academy
- integument 2 phase 3 trials
- atopic dermatitis
- prior inadequate response
- patient reported outcomes
- including intertriginous areas
- pediatric patients 6 years
- moderate atopic dermatitis
- pediatric patients 9 years
- severe liver impairment
- common adverse reactions
- plaque psoriasis include diarrhea
- application site pain
- upper respiratory tract infection
- urinary tract infection
- tmt newswire
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
ICYMI: EU Approves Upadacitinib for Severe Alopecia as US Review Remains Pending
1+ mon, 6+ day ago (38+ words) Dermatology Times The European Commission greenlights upadacitinib for severe alopecia areata, with phase 3 data showing rapid scalp, brow and lash regrowth; US decision still pending....